Identification

Name
Ipratropium bromide
Accession Number
DB00332  (APRD00537)
Type
Small Molecule
Groups
Approved
Description

A muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Structure
Thumb
Synonyms
  • (endo,syn)-(±)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide
  • 3α-hydroxy-8-isopropyl-1αH,5αH-tropanium bromide (±)-tropate
  • 8-Isopropylnoratropine methobromide
  • Bromure d'ipratropium
  • Bromuro de ipratropio
  • Ipratropii bromidum
  • Ipratropium bromide (anhydrous)
  • Ipratropium bromide anhydrous
  • Ipratropiumbromid
  • N-Isopropylnoratropinium bromomethylate
Product Ingredients
IngredientUNIICASInChI Key
Ipratropium bromide hydrateJ697UZ2A9J66985-17-9KEWHKYJURDBRMN-ZEODDXGYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AtroventSpray, metered42 ug/1NasalBoehringer Ingelheim1996-01-01Not applicableUs
AtroventSpray, metered42 ug/1NasalRemedy Repack2014-05-28Not applicableUs
AtroventSpray, metered21 ug/1NasalPhysicians Total Care, Inc.2006-03-31Not applicableUs
AtroventSpray, metered21 ug/1NasalBoehringer Ingelheim1996-01-01Not applicableUs
AtroventSolution250 mcgRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1988-12-312007-10-11Canada
Atrovent HFAAerosol, metered17 ug/1Respiratory (inhalation)Boehringer Ingelheim2005-05-01Not applicableUs
Atrovent HFAAerosol, metered17 ug/1Respiratory (inhalation)A S Medication Solutions2005-05-012017-06-20Us
Atrovent HFAAerosol, metered20 mcgRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee2004-03-24Not applicableCanada
Atrovent Nasal Aerosol 20mcg/aemAerosol20 mcgNasal; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1989-12-311999-08-09Canada
Atrovent Nasal SprayAerosol, metered0.03 %NasalSanofi Aventis1995-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ipravent Solution - Inh 250mcg/mlSolution250 mcgRespiratory (inhalation)Apotex Corporation1994-12-31Not applicableCanada
Apo-ipravent SterulesSolution0.025 %Respiratory (inhalation)Apotex Corporation1998-07-09Not applicableCanada
Apo-ipravent SterulesSolution125 mcgRespiratory (inhalation)Apotex Corporation2001-08-28Not applicableCanada
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2017-02-14Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Nephron Sc Inc.2001-09-27Not applicableUs
Ipratropium BromideSpray, metered42 ug/1NasalPhysicians Total Care, Inc.2004-04-12Not applicableUs
Ipratropium bromideSolution.5 mg/2.5mLRespiratory (inhalation)Aurobindo Pharma2016-10-27Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Mylan Pharmaceuticals2010-11-09Not applicableUs
Ipratropium BromideSpray, metered42 ug/1NasalBauch & Lomb Incorporated2003-03-31Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)St. Marys Medical Park Pharmacy2014-01-30Not applicableUs
International/Other Brands
Aerovent (Teva) / Apovent (Apotex Inc.) / Atronase (Boehringer Ingelheim) / Ipraxa (Ivax) / Ipvent (Cipla Medpro) / Rhinovent (Boehringer Ingelheim) / Rinatec (Boehringer Ingelheim) / Rinovagos (Valeas)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-salvent-ipravent SterulesIpratropium bromide (0.5 mg) + Salbutamol (2.5 mg)SolutionRespiratory (inhalation)Apotex Corporation2006-08-25Not applicableCanada
Combivent Inhalation AerosolIpratropium bromide (20 mcg) + Salbutamol sulfate (120 mcg)Aerosol, meteredOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1995-12-312007-10-02Canada
Combivent RespimatIpratropium bromide (20 mcg) + Salbutamol (100 mcg)SolutionRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee2014-09-16Not applicableCanada
Combivent RespimatIpratropium bromide (20 ug/1) + Salbutamol sulfate (120 ug/1)Spray, meteredRespiratory (inhalation)Boehringer Ingelheim2012-07-01Not applicableUs
Combivent UdvIpratropium bromide (0.2 mg) + Salbutamol (1 mg)SolutionRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1997-07-25Not applicableCanada
DuoNebIpratropium bromide (.5 mg/3mL) + Salbutamol sulfate (2.5 mg/3mL)SolutionRespiratory (inhalation)Mylan Specialty2011-02-152016-10-13Us
Duovent UdvIpratropium bromide (0.125 mg) + Fenoterol hydrobromide (0.3125 mg)SolutionOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1995-12-312017-01-31Canada
IpramolIpratropium bromide (0.5 mg) + Salbutamol (2.5 mg)SolutionRespiratory (inhalation)Ivax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Ipratropium Bromide and Albuterol SulfateIpratropium bromide (.5 mg/3mL) + Salbutamol sulfate (2.5 mg/3mL)SolutionRespiratory (inhalation)Mylan Pharmaceuticals2013-03-01Not applicableUs
Ipratropium Bromide and Albuterol SulfateIpratropium bromide (.5 mg/3mL) + Salbutamol sulfate (3 mg/3mL)SolutionRespiratory (inhalation)Mylan Pharmaceuticals2001-03-212016-10-13Us
Categories
UNII
VJV4X1P2Z1
CAS number
22254-24-6
Weight
Average: 412.361
Monoisotopic: 411.140906478
Chemical Formula
C20H30BrNO3
InChI Key
LHLMOSXCXGLMMN-VVQPYUEFSA-M
InChI
InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18+,19?,21+;
IUPAC Name
(1R,3R,5S,8R)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-8-ium bromide
SMILES
[Br-].[H][[email protected]]12CC[[email protected]]([H])(C[[email protected]@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[[email protected]+]2(C)C(C)C

Pharmacology

Indication

For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Structured Indications
Pharmacodynamics

Ipratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis.

Mechanism of action

Ipratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
AMuscarinic acetylcholine receptor M3
antagonist
Human
Absorption

Inhalation (local)-minimal; Nasal-rapid and minimal

Volume of distribution
  • 4.6 L/kg
Protein binding

Minimally (0 to 9% in vitro) bound to plasma albumin and α1-acid glycoproteins

Metabolism

Partially metabolized to at least 8 metabolites formed primarily via hydrolysis and conjugation. The main metabolites are N-isopropylnortropium methobromide, which is formed by enzymatic hydrolysis of the ester; α-phenylacrylic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a water; and phenylacetic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a CH3OH-group. These metabolites appear to be inactive.

Route of elimination

Primarily eliminated renally via active secretion.

Half life

2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t1/2 α) and terminal elimination-phase half-life (t1/2 β) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.

Clearance
  • 2.3 L/min (total clearance of active ingredient)
Toxicity

LD50=1001mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AbirateroneThe serum concentration of Ipratropium bromide can be increased when it is combined with Abiraterone.Approved
AclidiniumAclidinium may increase the anticholinergic activities of Ipratropium bromide.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ambenonium.Approved
AmiodaroneThe metabolism of Ipratropium bromide can be decreased when combined with Amiodarone.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Anisotropine Methylbromide.Approved
AprepitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Aprepitant.Approved, Investigational
ArtemetherThe metabolism of Ipratropium bromide can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Ipratropium bromide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atropine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium bromide.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ipratropium bromide.Approved
BetaxololThe metabolism of Ipratropium bromide can be decreased when combined with Betaxolol.Approved
BezitramideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Biperiden.Approved, Investigational
BoceprevirThe metabolism of Ipratropium bromide can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Bornaprine.Experimental
BortezomibThe metabolism of Ipratropium bromide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AIpratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BIpratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Ipratropium bromide can be decreased when combined with Bupropion.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Butorphanol.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Ipratropium bromide can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CelecoxibThe metabolism of Ipratropium bromide can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe metabolism of Ipratropium bromide can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe metabolism of Ipratropium bromide can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium bromide.Approved
CholecalciferolThe metabolism of Ipratropium bromide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Ipratropium bromide can be decreased when combined with Cimetidine.Approved
CimetropiumIpratropium bromide may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CinacalcetThe metabolism of Ipratropium bromide can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Ipratropium bromide can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Ipratropium bromide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ipratropium bromide can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Ipratropium bromide can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Ipratropium bromide can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Ipratropium bromide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Ipratropium bromide can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Ipratropium bromide can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Ipratropium bromide can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Ipratropium bromide can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe metabolism of Ipratropium bromide can be decreased when combined with Crizotinib.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Ipratropium bromide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Cyclopentolate.Approved
CyclosporineThe metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ipratropium bromide can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Ipratropium bromide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ipratropium bromide can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Demecarium.Approved
DesipramineThe metabolism of Ipratropium bromide can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Ipratropium bromide can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Ipratropium bromide can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Ipratropium bromide can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Donepezil.Approved
DosulepinThe metabolism of Ipratropium bromide can be decreased when combined with Dosulepin.Approved
DoxycyclineThe metabolism of Ipratropium bromide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with DPDPE.Investigational
DronabinolIpratropium bromide may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Ipratropium bromide can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Ipratropium bromide can be decreased when combined with Duloxetine.Approved
EchothiophateThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Edrophonium.Approved
EliglustatThe metabolism of Ipratropium bromide can be decreased when combined with Eliglustat.Approved
EluxadolineIpratropium bromide may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Emepronium.Experimental
EnzalutamideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Ipratropium bromide can be decreased when combined with Erythromycin.Approved, Vet Approved
EtanautineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.Approved
FluconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Ipratropium bromide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ipratropium bromide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ipratropium bromide can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Ipratropium bromide can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Gallamine Triethiodide.Approved
Glucagon recombinantThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.Approved
GlycopyrroniumIpratropium bromide may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HaloperidolThe metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.Approved
HeroinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium bromide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium bromide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hyoscyamine.Approved
IdelalisibThe serum concentration of Ipratropium bromide can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Ipratropium bromide can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Ipratropium bromide can be decreased when combined with Imipramine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Ipratropium bromide.Approved
IndinavirThe metabolism of Ipratropium bromide can be decreased when combined with Indinavir.Approved
IpidacrineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Ipratropium bromide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Ipratropium bromide can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Ipratropium bromide can be decreased when combined with Isradipine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Ipratropium bromide.Investigational
ItraconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ipratropium bromide can be increased when it is combined with Ivacaftor.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Ketoconazole.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Lofentanil.Illicit
LopinavirThe metabolism of Ipratropium bromide can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Ipratropium bromide can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Ipratropium bromide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Ipratropium bromide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ipratropium bromide can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ipratropium bromide can be decreased when combined with Lumefantrine.Approved
MalathionThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineThe metabolism of Ipratropium bromide can be decreased when combined with Manidipine.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Meptazinol.Experimental
MethadoneThe metabolism of Ipratropium bromide can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methantheline.Approved, Investigational
MethotrimeprazineThe metabolism of Ipratropium bromide can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.Approved
MetoprololThe metabolism of Ipratropium bromide can be decreased when combined with Metoprolol.Approved, Investigational
MianserinMianserin may increase the anticholinergic activities of Ipratropium bromide.Approved, Investigational
MidostaurinThe metabolism of Ipratropium bromide can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Ipratropium bromide can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mirabegron.Approved
MitotaneThe serum concentration of Ipratropium bromide can be decreased when it is combined with Mitotane.Approved
MorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Morphine.Approved, Investigational
NabiloneIpratropium bromide may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Nalbuphine.Approved
NefazodoneThe metabolism of Ipratropium bromide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ipratropium bromide can be decreased when combined with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ipratropium bromide can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Ipratropium bromide can be decreased when combined with Nicardipine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Nicomorphine.Experimental
NilotinibThe metabolism of Ipratropium bromide can be decreased when combined with Nilotinib.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Normethadone.Approved, Illicit
OlaparibThe metabolism of Ipratropium bromide can be decreased when combined with Olaparib.Approved
OpiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Otilonium.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxyphenonium.Approved
PalbociclibThe serum concentration of Ipratropium bromide can be increased when it is combined with Palbociclib.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Ipratropium bromide can be increased when it is combined with Panobinostat.Approved, Investigational
ParaoxonThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Paraoxon.Experimental
ParoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Ipratropium bromide can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Phenglutarimide.Experimental
PhenobarbitalThe metabolism of Ipratropium bromide can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Phenoperidine.Experimental
PhenytoinThe metabolism of Ipratropium bromide can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Ipratropium bromide.Approved
PosaconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideIpratropium bromide may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Ipratropium bromide.Approved, Investigational
PrimidoneThe metabolism of Ipratropium bromide can be increased when combined with Primidone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Procyclidine.Approved
PromazineThe metabolism of Ipratropium bromide can be decreased when combined with Promazine.Approved, Vet Approved
PropanthelineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propiverine.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Ipratropium bromide.Approved
QuinidineThe metabolism of Ipratropium bromide can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Ipratropium bromide can be decreased when combined with Quinine.Approved
RamosetronIpratropium bromide may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe metabolism of Ipratropium bromide can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Remifentanil.Approved
RifabutinThe metabolism of Ipratropium bromide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ipratropium bromide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ipratropium bromide can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Ipratropium bromide can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Ipratropium bromide can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Ipratropium bromide can be decreased when combined with Ropinirole.Approved, Investigational
SaquinavirThe metabolism of Ipratropium bromide can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide.Approved, Investigational
SertralineThe metabolism of Ipratropium bromide can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Ipratropium bromide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ipratropium bromide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ipratropium bromide can be increased when it is combined with Simeprevir.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Solifenacin.Approved
St. John's WortThe serum concentration of Ipratropium bromide can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Ipratropium bromide can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Ipratropium bromide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ipratropium bromide.Approved, Investigational
TacrineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tapentadol.Approved
TelaprevirThe metabolism of Ipratropium bromide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ipratropium bromide can be decreased when combined with Telithromycin.Approved
TerbinafineThe metabolism of Ipratropium bromide can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
ThioridazineThe metabolism of Ipratropium bromide can be decreased when combined with Thioridazine.Approved, Withdrawn
TiclopidineThe metabolism of Ipratropium bromide can be decreased when combined with Ticlopidine.Approved
TilidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tilidine.Experimental
TiotropiumIpratropium bromide may increase the anticholinergic activities of Tiotropium.Approved
TipranavirThe metabolism of Ipratropium bromide can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Ipratropium bromide can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tramadol.Approved, Investigational
TranylcypromineThe metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.Approved
TrichlorfonThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium bromide.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trihexyphenidyl.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trimethaphan.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Ipratropium bromide.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.Approved
VenlafaxineThe metabolism of Ipratropium bromide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ipratropium bromide can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Ipratropium bromide can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

Synthesis Reference

Abdine HH, Belala F, and Al-Badra AA. (2003). Ipratropium bromide: Methods of chemical and biochemical synthesis. In H.G. Brittain (Ed.). Profiles of drug substances, excipients and related methodology (pp. 85-99). Amsterdam, Netherlands: Elsevier Academic Press.

General References
  1. Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y: [Antiallergic asthma effect of ipatropium bromide (Sch 1000) in dogs (author's transl)]. Nihon Yakurigaku Zasshi. 1977 Oct;73(7):785-91. [PubMed:145994]
External Links
Human Metabolome Database
HMDB14476
KEGG Compound
C07052
PubChem Compound
657308
PubChem Substance
46506138
ChemSpider
21865423
ChEBI
46659
ChEMBL
CHEMBL1908368
Therapeutic Targets Database
DNC000806
PharmGKB
PA450082
IUPHAR
325
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ipratropium_bromide
ATC Codes
R03BB01 — Ipratropium bromideR03AL01 — Fenoterol and ipratropium bromideR03AL02 — Salbutamol and ipratropium bromideR01AX03 — Ipratropium bromide
AHFS Codes
  • 12:08.08 — Antimuscarinics Antispasmodics
FDA label
Download (88.1 KB)
MSDS
Download (72.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic SciencePulmonary Disease, Chronic Obstructive1
1CompletedDiagnosticPulmonary Disease, Chronic Obstructive1
1RecruitingTreatmentStatus Asthmaticus1
2CompletedDiagnosticLung Diseases, Obstructive1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)4
2CompletedTreatmentParkinson's Disease (PD)1
2CompletedTreatmentPulmonary Disease, Chronic Obstructive2
2Not Yet RecruitingTreatmentExercise Induced Laryngeal Obstruction (EILO)1
3CompletedPreventionChronic Lung Diseases / Chronic Obstructive Pulmonary Disease (COPD) / Lung Diseases, Obstructive1
3CompletedTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease1
3CompletedTreatmentAsthma Bronchial1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentFamilial Dysautonomia1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive8
3RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Airways Disease / Chronic Obstructive Pulmonary Disease Exacerbation1
4Active Not RecruitingTreatmentAsthma Bronchial1
4CompletedDiagnosticAsthma Bronchial1
4CompletedSupportive CareChronic Obstructive Pulmonary Disease (COPD) / Sepsis / Shock1
4CompletedTreatmentAcute Asthma / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)3
4CompletedTreatmentCold1
4CompletedTreatmentExercise-Induced Bronchoconstriction (EIB)1
4CompletedTreatmentPulmonary Disease, Chronic Obstructive5
4RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentAsthma Bronchial1
4TerminatedTreatmentAsthma Bronchial1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailableDyspnea / Quadriplegia1
Not AvailableCompletedNot AvailablePulmonary Disease, Chronic Obstructive6
Not AvailableCompletedNot AvailableAcute Rhinitis1
Not AvailableCompletedDiagnosticChronic Obstructive Pulmonary Disease (COPD)2
Not AvailableCompletedTreatmentAnaesthesia therapy / Extravascular Lung Water / Intensive Care, Surgical / Lung Injury, Acute / Thoracotomy1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableCompletedTreatmentBronchitis1
Not AvailableNot Yet RecruitingNot AvailableLung Diseases, Interstitial1
Not AvailableNot Yet RecruitingTreatmentAsthma Acute / Asthma in Children1
Not AvailableTerminatedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusNot AvailableElectrophysiological Parameters / Influence of Nebulized Bronchodilatators on Selected1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1

Pharmacoeconomics

Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis mid atlantic llc
  • Bausch and lomb pharmaceuticals inc
  • Cobalt laboratories inc
  • Dey lp
  • Holopack international corp
  • Landela pharmaceutical
  • Nephron corp
  • Novex pharma
  • Pharmascience inc
  • Roxane laboratories inc
  • Teva parenteral medicines inc
  • Bausch and lomb inc
Packagers
Dosage forms
FormRouteStrength
SolutionRespiratory (inhalation)250 mcg
Spray, meteredNasal21 ug/1
Aerosol, meteredRespiratory (inhalation)17 ug/1
Aerosol, meteredRespiratory (inhalation)20 mcg
AerosolNasal; Respiratory (inhalation)20 mcg
Aerosol, meteredNasal0.03 %
Aerosol, meteredNasal0.06 %
Aerosol, meteredOral; Respiratory (inhalation)
Spray, meteredRespiratory (inhalation)
LiquidNasal; Respiratory (inhalation)0.03 %
LiquidRespiratory (inhalation)125 mcg
LiquidRespiratory (inhalation)250 mcg
SolutionOral; Respiratory (inhalation)
LiquidRespiratory (inhalation)0.30 mg
SolutionRespiratory (inhalation).5 mg/2.5mL
SprayNasal21 ug/1
SprayNasal42 ug/1
Spray, meteredNasal42 ug/1
InhalantRespiratory (inhalation)
SolutionRespiratory (inhalation)
SolutionNasal0.03 %
SolutionNasal0.06 %
SolutionRespiratory (inhalation)0.25 mg
SolutionRespiratory (inhalation).25 mg
LiquidRespiratory (inhalation)0.25 mg
LiquidRespiratory (inhalation)0.03 %
Spray, meteredNasal21 mcg
SolutionNasal; Respiratory (inhalation)250 mcg
SolutionRespiratory (inhalation)125 mcg
SolutionRespiratory (inhalation)0.025 %
Prices
Unit descriptionCostUnit
Atrovent HFA 17 mcg/act Aerosol 12.9 gm Inhaler143.59USD inhaler
Ipratropium bromide powder100.06USD g
Atrovent 0.03% Solution 30ml Nasal Spray96.95USD bottle
Atrovent 0.06% Solution 15ml Nasal Spray84.68USD bottle
Ipratropium Bromide 0.03% Solution 30ml Bottle53.82USD bottle
Ipratropium Bromide 0.06% Solution 15ml Bottle46.14USD bottle
Ipratropium Bromide 0.02% Solution Each Box Contains Twenty-Five 2.5ml Vials45.86USD box
Atrovent hfa inhaler11.89USD g
Atrovent 0.06% spray5.33USD ml
Atrovent 0.03% spray3.11USD ml
Ipratropium 0.06% spray2.96USD ml
Ipratropium 0.03% spray1.73USD ml
Atrovent 0.03 % Spray1.04USD ml
Apo-Ipravent 250 mcg/ml Solution0.58USD ml
Mylan-Ipratropium 250 mcg/ml Solution0.58USD ml
Novo-Ipramide 250 mcg/ml Solution0.58USD ml
Pms-Ipratropium 0.03 % Spray0.58USD ml
Pms-Ipratropium 250 mcg/ml Solution0.58USD ml
Atrovent Hfa 20 mcg/dose Metered Dose Aerosol0.1USD metered dose aerosol
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5766573No1992-11-282009-11-28Us
CA2151383No2005-02-082013-12-06Canada
US6632842No2001-12-282021-12-28Us
US8474447No2010-01-172030-01-17Us
US6739333No2000-05-262020-05-26Us
US6983743No2000-05-262020-05-26Us
US6453795Yes1997-06-052017-06-05Us
US8733341Yes2011-04-162031-04-16Us
US9027967Yes2007-10-012027-10-01Us
US7104470Yes1997-04-042017-04-04Us
US7246615Yes1996-12-012016-12-01Us
US7896264Yes2005-11-262025-11-26Us
US7988001Yes2002-02-042022-02-04Us
US7802568Yes1999-08-262019-08-26Us
US6149054Yes1997-06-162017-06-16Us
US6726124Yes1997-04-042017-04-04Us
US7396341Yes2007-04-102027-04-10Us
US6846413Yes1999-02-282019-02-28Us
US6176442Yes1996-12-012016-12-01Us
US7837235Yes2008-09-132028-09-13Us
US5964416Yes1997-04-042017-04-04Us
US7284474Yes2005-02-262025-02-26Us
US6977042Yes1999-02-282019-02-28Us
US6988496Yes2000-08-232020-08-23Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)230-231.5U.S. Patent 3,505,337
water solubilityFreely solubleNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000701 mg/mLALOGPS
logP0.21ALOGPS
logP-1.8ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity105.9 m3·mol-1ChemAxon
Polarizability37.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9425
Blood Brain Barrier+0.8883
Caco-2 permeable+0.6619
P-glycoprotein substrateSubstrate0.5085
P-glycoprotein inhibitor INon-inhibitor0.8489
P-glycoprotein inhibitor IINon-inhibitor0.5964
Renal organic cation transporterInhibitor0.6651
CYP450 2C9 substrateNon-substrate0.7214
CYP450 2D6 substrateNon-substrate0.7637
CYP450 3A4 substrateSubstrate0.6657
CYP450 1A2 substrateNon-inhibitor0.8412
CYP450 2C9 inhibitorNon-inhibitor0.9118
CYP450 2D6 inhibitorNon-inhibitor0.8915
CYP450 2C19 inhibitorNon-inhibitor0.8783
CYP450 3A4 inhibitorNon-inhibitor0.9396
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9528
Ames testNon AMES toxic0.7112
CarcinogenicityNon-carcinogens0.8979
BiodegradationReady biodegradable0.5154
Rat acute toxicity2.7983 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9596
hERG inhibition (predictor II)Inhibitor0.5879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tropane alkaloids. These are organic compounds containing the nitrogenous bicyclic alkaloid parent N-Methyl-8-azabicyclo[3.2.1]octane.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Tropane alkaloids
Sub Class
Not Available
Direct Parent
Tropane alkaloids
Alternative Parents
Beta hydroxy acids and derivatives / Piperidines / Benzene and substituted derivatives / N-alkylpyrrolidines / Tetraalkylammonium salts / Carboxylic acid esters / Azacyclic compounds / Monocarboxylic acids and derivatives / Organic bromide salts / Hydrocarbon derivatives
show 6 more
Substituents
Tropane alkaloid / Beta-hydroxy acid / Monocyclic benzene moiety / Hydroxy acid / Piperidine / N-alkylpyrrolidine / Benzenoid / Tetraalkylammonium salt / Pyrrolidine / Quaternary ammonium salt
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic bromide salt (CHEBI:46659)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Keam SJ, Keating GM: Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68. [PubMed:15350163]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Keam SJ, Keating GM: Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68. [PubMed:15350163]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I: Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95. doi: 10.1021/mp900206j. [PubMed:20020740]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I: Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95. doi: 10.1021/mp900206j. [PubMed:20020740]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33